戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ocytochemistry (e.g., insulin, glucagon, and pancreatic polypeptide).
2 n, peptide YY, cholecystokinin, insulin, and pancreatic polypeptide.
3 secretion by the gut hormones peptide YY and pancreatic polypeptide.
4 ls also produced glucagon, somatostatin, and pancreatic polypeptide.
5 a levels of epinephrine, norepinephrine, and pancreatic polypeptide.
6 rmones: insulin, glucagon, somatostatin, and pancreatic polypeptide.
7  +/- 424 pmol/l, respectively; P < 0.05) and pancreatic polypeptide (97 +/- 32 and 98 +/- 8 vs. 223 +
8                     Administration of either pancreatic polypeptide (a strong agonist of the receptor
9 proach, the small, well-folded protein avian pancreatic polypeptide acts as a scaffold to present and
10 re, the interaction of receptor mutants with pancreatic polypeptide analogs was studied through doubl
11  the model PEGylated peptides, 20K PEGylated-Pancreatic Polypeptide analogue (PPA) and 20K PEGylated-
12 ic hormones insulin, glucagon, somatostatin, pancreatic polypeptide and ghrelin.
13  2 responses of epinephrine, norepinephrine, pancreatic polypeptide and MSNA compared to day 1 cortis
14  detected the presence of insulin, glucagon, pancreatic polypeptide and somatostatin-producing cells
15 ities blunted key autonomic (epinephrine and pancreatic polypeptide) and metabolic (endogenous glucos
16 in, glucagon, vasoactive intestinal peptide, pancreatic polypeptide, and 24-hour urinary 5-hydroxyind
17  and high-density lipoprotein (HDL), leptin, pancreatic polypeptide, and amylin.
18 e, norepinephrine, glucagon, growth hormone, pancreatic polypeptide, and cortisol levels, was signifi
19 e AR42J cells to differentiate into insulin, pancreatic polypeptide, and glucagon-positive cells.
20 ents in subsequent glucagon, growth hormone, pancreatic polypeptide, and muscle sympathetic nerve act
21  leptin, monocyte chemoattractant protein-1, pancreatic polypeptide, and peptide YY.
22 de YY (PYY), oxyntomodulin (enteroglucagon), pancreatic polypeptide, and somatostatin.
23 cluding insulin, glucagon, somatostatin, and pancreatic polypeptide; and B cell transcription factors
24 l face of the small yet stable protein avian pancreatic polypeptide (aPP).
25 es encoding receptors with high affinity for pancreatic polypeptide are not clustered with the genes
26 5%), beta-cells (92%), delta-cells (1%), and pancreatic polypeptide cells (2%).
27  conversion of beta-cells lacking Abcc8 into pancreatic polypeptide cells but not to alpha- or delta-
28  subunits were expressed in alpha, beta, and pancreatic polypeptide cells, whereas kainate receptors
29 -c-peptide, fibrinogen, alpha-1-antitrypsin, pancreatic polypeptide, complement C3, vitronectin, cort
30  and percentage body fat) and fasting plasma pancreatic polypeptide concentrations (both before and a
31 dies resulted in significantly higher plasma pancreatic polypeptide concentrations compared with the
32                           Plasma insulin and pancreatic polypeptide concentrations peaked at 250% and
33                Adjustment for fasting plasma pancreatic polypeptide concentrations, a marker of paras
34 hologic dedifferentiation of beta-cells to a pancreatic polypeptide-fold hormone-positive state.
35 ease in gastric acid output, a rise in serum pancreatic polypeptide following sham feeding, and prese
36 2 did not alter epinephrine, norepinephrine, pancreatic polypeptide, free fatty acid, or endogenous g
37 pha-helix onto a small stable protein, avian pancreatic polypeptide, generated a helical 30-amino-aci
38 s, steady state epinephrine, norepinephrine, pancreatic polypeptide, glucagon, ACTH and muscle sympat
39  2 steady state epinephrine, norepinephrine, pancreatic polypeptide, glucagon, growth hormone, and mu
40  and fasting plasma concentrations of GLP-1, pancreatic polypeptide, glucose, and insulin.
41 an Y4 receptor (hY4R) interaction with human pancreatic polypeptide (hPP) is crucial, not only for un
42 also higher Y(4)R affinity compared to human pancreatic polypeptide (hPP).
43 y [Leu(31),Pro(34)]NPY, NPY(13-36) and human pancreatic polypeptide (hPP).
44  the binding pocket of the endogenous ligand pancreatic polypeptide in the core of the Y(4)R transmem
45              This compound attenuated bovine pancreatic polypeptide induced food intake in rats but f
46 and masking any binding to Y4 using 1 nM rat pancreatic polypeptide left a small amount of binding re
47  YY, glucagon-like peptide 1, oxyntomodulin, pancreatic polypeptide, leptin, and adiponectin concentr
48 ect group of patients identified an elevated pancreatic polypeptide level and pancreatic tail mass le
49 ypoglycemia-induced increase in the arterial pancreatic polypeptide level.
50                                              Pancreatic polypeptide levels tended to increase in CON
51 ine, glucagon, growth hormone, cortisol, and pancreatic polypeptide levels were similarly significant
52 rine, muscle sympathetic nerve activity, and pancreatic polypeptide), neuroendocrine (glucagon and gr
53 dditional significant blunting (P < 0.01) of pancreatic polypeptide, norepinephrine, growth hormone,
54 ed derivatives of the endogenous YR agonists pancreatic polypeptide or peptide YY.
55 (4) receptor (Y(4)R) is unique as it prefers pancreatic polypeptide over NPY and peptide YY.
56 her reduced the epinephrine (P = 0.0001) and pancreatic polypeptide (P = 0.0030) responses, tended to
57 e (P = 0.0027), norepinephrine (P = 0.0007), pancreatic polypeptide (P = 0.0030), and neurogenic symp
58 0), perhaps norepinephrine (P = 0.0838), and pancreatic polypeptide (P = 0.0034) responses to hypogly
59  (P = 0.0094), epinephrine (P = 0.0063), and pancreatic polypeptide (P = 0.0046) responses to stepped
60  = 0.6270), neurogenic symptom (P = 0.6470), pancreatic polypeptide (P = 0.0629), or glucagon (P = 0.
61 a-cell-associated genes (IAPP [islet amyloid pancreatic polypeptide], PDX-1 [pancreatic and duodenal
62 rogenitor stage, but favor somatostatin- and pancreatic polypeptide-positive cells at the expense of
63 , 12.1%+/-0.7% somatostatin, and 1.5%+/-0.2% pancreatic polypeptide-positive cells.
64 hobiology and shows differential dynamics of pancreatic polypeptide (PP) cell abundance and CD8(+) T
65  absence of peptide YY with the exception of pancreatic polypeptide (PP) cells, indicating that pepti
66 rticularly the less abundant delta and gamma/pancreatic polypeptide (PP) cells.
67                     Neuropeptide Y (NPY) and pancreatic polypeptide (PP) control central and peripher
68 ural ligands of Y(5) R, peptide YY (PYY) and pancreatic polypeptide (PP) dock to the receptor in a si
69 ects of peptides of the neuropeptide Y (NPY)/pancreatic polypeptide (PP) family on synaptic transmiss
70  (PYY), glucagon-like-peptide-1 (GLP-1), and pancreatic polypeptide (PP) in humans and rodents follow
71                                              Pancreatic polypeptide (PP) increased by 62%, 5 min afte
72                                              Pancreatic polypeptide (PP) is a regulatory peptide that
73                                              Pancreatic polypeptide (PP) is released from the pancrea
74 the pancreas as assessed by increased plasma pancreatic polypeptide (PP) levels (delta = 135.0 +/- 36
75                                              Pancreatic polypeptide (PP) microinjected into the dorsa
76 malian neuropeptide Y (NPY)/peptide YY (PYY)/pancreatic polypeptide (PP) receptors comprises several
77                              To determine if pancreatic polypeptide (PP) secretion is likewise involv
78 example, in the neuropeptide Y (NPY) family, pancreatic polypeptide (PP) shows significant structural
79 perinsulinemia and elevated plasma levels of pancreatic polypeptide (PP), an islet hormone considered
80  1 (GLP-1), peptide tyrosine tyrosine (PYY), pancreatic polypeptide (PP), and leptin.
81  neuropeptide Y (NPY), peptide YY (PYY), and pancreatic polypeptide (PP), are found in the central an
82 an Y4 receptor (Y4R) and its cognate ligand, pancreatic polypeptide (PP), are involved in the regulat
83 he related peptide YY(3-36) (PYY(3-36)), and pancreatic polypeptide (PP), important modulators of ARC
84 -receptor (Y(4)R) and its endogenous ligand, pancreatic polypeptide (PP), suppress appetite in respon
85 ogenous peptides, i.e., NPY, peptide YY, and pancreatic polypeptide (PP), the latter showing a prefer
86 eptide 1 analogue, cholecystokinin (CCK) and pancreatic polypeptide (PP).
87 on preferences for NPY, peptide YY (PYY), or pancreatic polypeptide (PP).
88 he endocrine peptides, peptide YY (PYY), and pancreatic polypeptide (PP).
89 ffinity (Kd = 2.8 nM) for 125I-labeled human pancreatic polypeptide (PP).
90 31, Pro34]NPY (Y1/Y5), NPY (Y3/Y1/Y5/Y2) and pancreatic polypeptide (PP, Y4) injected i.c. at 500 ng
91 ribed Y1, Y2 and Y3 NPY receptors and the Y4 pancreatic polypeptide- (PP-) preferring receptor.
92                                              Pancreatic polypeptides (PPs) such as neuropeptide Y (NP
93                         Peptide YY (PYY) and pancreatic polypeptide (PPY) are members of the neuropep
94                     The cellular identity of pancreatic polypeptide (Ppy)-expressing y-cells, one of
95 islet non-beta-cells, namely alpha-cells and pancreatic polypeptide (PPY)-producing gamma-cells, obta
96 ells, somatostatin-producing delta cells and pancreatic polypeptide-producing PP cells.
97 ny of the normal islet cell types except for pancreatic-polypeptide-producing cells.
98  as assessed by 70% reductions of the plasma pancreatic polypeptide response and epinephrine response
99 tion was measured by gastric acid output and pancreatic polypeptide response to sham feeding.
100 th hormone, epinephrine, norepinephrine, and pancreatic polypeptide responses during day 2 exercise w
101 lucose-dependent insulinotropic peptide, and pancreatic polypeptide responses were reduced in gastric
102 r of the transplanted groups (IH and IP) had pancreatic polypeptide responses.
103 ephrine), and parasympathetic neural (plasma pancreatic polypeptide)-responses to hypoglycemia were n
104 exin neurons, we examined the effects of rat pancreatic polypeptide (rPP), a Y4-selective ligand, or
105                                     However, pancreatic polypeptide, somatostatin, and ghrelin cells
106 5% of NETs demonstrated focal positivity for pancreatic polypeptide, somatostatin, insulin, and/or gl
107                                              Pancreatic polypeptide was significantly lower (P < 0.05
108                  Modeling based on the avian pancreatic polypeptide X-ray structure suggested that an
109           Guinea-pig neuropeptide Y1 and rat pancreatic polypeptide Y4 receptors expressed in Chinese

 
Page Top